Toronto, Ontario--(Newsfile Corp. - September 5, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen"), is pleased to announce that Richard Buzbuzian, NuGen's President, CEO and Director, and Karen Dunlap, Chief Customer Officer and Director, are scheduled to present at the 2023 Kinvestor Days Virtual Conference on September 20, 2023, at 9:00 am PT (12:00 pm ET). More details below.

This year's Kinvestor Days is a 2-day virtual conference featuring a stellar lineup of presenting companies in the technology and mining industries. Hosted by Kin Communications' president Arlen Hansen, presenting companies will have the opportunity to share their latest developments and answer thoughtful questions from attendees.

Register for free today and reserve your spot to hear from Richard, Karen and other key executives as they discuss the latest in technology, mining, and battery metals.

Presentation Details:

Date: September 20, 2023
Presentation Time: 9:00 am PT / 12:00 pm ET
Presenters:
Richard Buzbuzian, President, CEO and Director
Karen Dunlap, Chief Customer Officer and Director

Register now at https://us06web.zoom.us/webinar/register/1916911734480/WN_T-UkYKxYR66v8mUFoVsxGw

About Kinvestor Virtual Conferences

Kinvestor creates powerful opportunities for investors to connect with both established and up-and-coming public companies in the mining, technology, and energy sectors on a free-to-join virtual platform. Kinvestor Virtual Conferences are powered by Kin Communications Inc., a full-service investor relations agency with over 14 years of experience across multiple industries.

Kinvestor's goal is to foster long-term relationships with investors, thought leaders and the media. Kinvestor's investor relations services include strategy, messaging, investor outreach, digital marketing, content creation, and more.

For more information, please visit: www.kinvestor.net

Twitter: @kincomm

About NuGen

NuGen is a specialty medical device Company that is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics. InsuJet™ is approved for sale in 42 countries around the world.

For further information, please visit:

Websites: www.insujet.com and www.nugenmd.com
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/

For further information, please contact:

Tony Di Benedetto
Executive Chairman
(416) 791-9399
This email address is being protected from spambots. You need JavaScript enabled to view it.

Richard Buzbuzian
President & CEO
(647) 501-3290
This email address is being protected from spambots. You need JavaScript enabled to view it.

To arrange a media interview with NuGen, please contact:

Morna Gorman
(416) 553-1732
This email address is being protected from spambots. You need JavaScript enabled to view it.

Notice Regarding Forward-Looking Information

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.